Keytruda (pembrolizumab) - Merck (MSD)
Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
DS-8201 + Keytruda: Initiation of P1b trial (NCT04042701) for breast cancer in Q4 FY 2019 (Daiichi Sankyo) - Feb 1, 2020 - Q3 FY 2019 Results 
Trial initiation date
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005468/FY2019%20Q3%20Presentation%20Material.pdf
 
Feb 1, 2020
 
 
e2e45bc5-f406-40c8-94a2-93b62d2dc4d5.jpg